Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | May 23, 2020
Product Development
TIGIT breaks through as next-generation checkpoint target
ASCO preview: TIGIT’s dual role in immunity could position it to lead among next-gen checkpoints
BioCentury | May 15, 2020
Product Development
TIGIT emerges as a standout next generation checkpoint target at ASCO
Data for next generation checkpoint targets from Roche, MacroGenics unveiled in ASCO abstracts
BioCentury | Oct 19, 2019
Product Development
How GSK has rebuilt its oncology pipeline from the ground up
Two years into its cancer rebuild, GSK's strategy to break into immuno-oncology may soon start to pay off
BioCentury | Oct 19, 2019
Product Development
Tracking the rise and fall of next-generation checkpoint targets for cancer
BioCentury’s analysis of next-generation checkpoint targets finds three that are gathering steam
BioCentury | Apr 6, 2019
Finance
Big caps under pressure
Buysiders eye gene therapy, SMID-cap catalysts in 2Q19
BioCentury | Dec 20, 2018
Finance
Third Rock keeps its options open
Why Third Rock likes multi-asset option deals for its newcos
BioCentury | Jul 19, 2018
Tools & Techniques
Immunotherapy Matchmaking
How MD Anderson is using its access to clinical samples to home in on better immunotherapy combos
Items per page:
1 - 10 of 25